[S02DA03, antipyrine, The metabolism of Antipyrine can be increased when combined with Secukinumab.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Secukinumab.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Secukinumab.]
[L04AA27, fingolimod, Secukinumab may increase the immunosuppressive activities of Fingolimod.]
[J01EC02, sulfadiazine, The metabolism of Sulfadiazine can be increased when combined with Secukinumab.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Secukinumab.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be increased when combined with Secukinumab.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Secukinumab.]
[N06DA01, tacrine, The metabolism of Tacrine can be increased when combined with Secukinumab.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Secukinumab.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Secukinumab.]
[G03BA03, testosterone, The metabolism of Testosterone can be increased when combined with Secukinumab.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be increased when combined with Secukinumab.]
[A04AD10, dronabinol, The metabolism of Dronabinol can be increased when combined with Secukinumab.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be increased when combined with Secukinumab.]
[L04AX02, thalidomide, The metabolism of Thalidomide can be increased when combined with Secukinumab.]
[R03DA07, theobromine, The metabolism of Theobromine can be increased when combined with Secukinumab.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Secukinumab.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be increased when combined with Secukinumab.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Secukinumab.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Secukinumab.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Secukinumab.]
[N05CA19, thiopental, The metabolism of Thiopental can be increased when combined with Secukinumab.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be increased when combined with Secukinumab.]
[N05AF04, thiothixene, The metabolism of Thiothixene can be increased when combined with Secukinumab.]
[C01BB04, aprindine, The metabolism of Aprindine can be increased when combined with Secukinumab.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be increased when combined with Secukinumab.]
[S01ED01, timolol, The metabolism of Timolol can be increased when combined with Secukinumab.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be increased when combined with Secukinumab.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be increased when combined with Secukinumab.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Secukinumab.]
[N06AX05, trazodone, The metabolism of Trazodone can be increased when combined with Secukinumab.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be increased when combined with Secukinumab.]
[S01BA05, triamcinolone, The metabolism of Triamcinolone can be increased when combined with Secukinumab.]
[C03DB02, triamterene, The metabolism of Triamterene can be increased when combined with Secukinumab.]
[N05CD05, triazolam, The metabolism of Triazolam can be increased when combined with Secukinumab.]
[N05AB06, trifluoperazine, The metabolism of Trifluoperazine can be increased when combined with Secukinumab.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Secukinumab.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Secukinumab is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Secukinumab.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be increased when combined with Secukinumab.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be increased when combined with Secukinumab.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be increased when combined with Secukinumab.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be increased when combined with Secukinumab.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Secukinumab.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Secukinumab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Ipilimumab is combined with Secukinumab.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Secukinumab.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be increased when combined with Secukinumab.]
[J05AP03, boceprevir, The metabolism of Boceprevir can be increased when combined with Secukinumab.]
[J05AP02, telaprevir, The metabolism of Telaprevir can be increased when combined with Secukinumab.]
[J05AG05, rilpivirine, The metabolism of Rilpivirine can be increased when combined with Secukinumab.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Secukinumab.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be increased when combined with Secukinumab.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be increased when combined with Secukinumab.]
[C08DA01, verapamil, The metabolism of Verapamil can be increased when combined with Secukinumab.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Secukinumab.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Secukinumab.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Secukinumab.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Secukinumab.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be increased when combined with Secukinumab.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be increased when combined with Secukinumab.]
[J05AE02, indinavir, The metabolism of Indinavir can be increased when combined with Secukinumab.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Secukinumab.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Secukinumab.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Secukinumab.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be increased when combined with Secukinumab.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be increased when combined with Secukinumab.]
[N05AE04, ziprasidone, The metabolism of Ziprasidone can be increased when combined with Secukinumab.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Secukinumab.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Secukinumab.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be increased when combined with Secukinumab.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Secukinumab.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be increased when combined with Secukinumab.]
[C07AB03, atenolol, The metabolism of Atenolol can be increased when combined with Secukinumab.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Secukinumab.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Secukinumab.]
[J02AC03, voriconazole, The metabolism of Voriconazole can be increased when combined with Secukinumab.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be increased when combined with Secukinumab.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Secukinumab.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be increased when combined with Secukinumab.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Secukinumab is combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Secukinumab.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be increased when combined with Secukinumab.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Secukinumab.]
[G04BE10, avanafil, The metabolism of Avanafil can be increased when combined with Secukinumab.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Secukinumab.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Secukinumab.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Pertuzumab is combined with Secukinumab.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be increased when combined with Secukinumab.]
[G04BD12, mirabegron, The metabolism of Mirabegron can be increased when combined with Secukinumab.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Carfilzomib is combined with Secukinumab.]
[V03AX03, cobicistat, The metabolism of Cobicistat can be increased when combined with Secukinumab.]
[L02BB04, enzalutamide, The metabolism of Enzalutamide can be increased when combined with Secukinumab.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Secukinumab.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Secukinumab.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Secukinumab.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Secukinumab.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Secukinumab.]
[N05CA04, barbital, The metabolism of Barbital can be increased when combined with Secukinumab.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be increased when combined with Secukinumab.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be increased when combined with Secukinumab.]
[C08CA13, lercanidipine, The metabolism of Lercanidipine can be increased when combined with Secukinumab.]
[N06DA02, donepezil, The metabolism of Donepezil can be increased when combined with Secukinumab.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Secukinumab.]
[L04AA29, tofacitinib, Secukinumab may increase the immunosuppressive activities of Tofacitinib.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be increased when combined with Secukinumab.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be increased when combined with Secukinumab.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be increased when combined with Secukinumab.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be increased when combined with Secukinumab.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Secukinumab.]
[B01AF02, apixaban, The metabolism of Apixaban can be increased when combined with Secukinumab.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Secukinumab.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Raxibacumab is combined with Secukinumab.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be increased when combined with Secukinumab.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Secukinumab.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be increased when combined with Secukinumab.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Secukinumab.]
[A06AX06, tegaserod, The metabolism of Tegaserod can be increased when combined with Secukinumab.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be increased when combined with Secukinumab.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be increased when combined with Secukinumab.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Secukinumab.]
[N04AC01, benztropine, The metabolism of Benzatropine can be increased when combined with Secukinumab.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be increased when combined with Secukinumab.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be increased when combined with Secukinumab.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Secukinumab.]
[C08EA02, bepridil, The metabolism of Bepridil can be increased when combined with Secukinumab.]
[C02KX05, riociguat, The metabolism of Riociguat can be increased when combined with Secukinumab.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be increased when combined with Secukinumab.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be increased when combined with Secukinumab.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be increased when combined with Secukinumab.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be increased when combined with Secukinumab.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Secukinumab.]
[L04AA32, apremilast, The metabolism of Apremilast can be increased when combined with Secukinumab.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Secukinumab.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be increased when combined with Secukinumab.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Secukinumab.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Ramucirumab is combined with Secukinumab.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Secukinumab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Secukinumab.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Secukinumab.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Secukinumab.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be increased when combined with Secukinumab.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Secukinumab is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Secukinumab.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be increased when combined with Secukinumab.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Pembrolizumab.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Secukinumab is combined with Dulaglutide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Secukinumab.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be increased when combined with Secukinumab.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Secukinumab.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Blinatumomab.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be increased when combined with Secukinumab.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Secukinumab.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Nivolumab.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be increased when combined with Secukinumab.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be increased when combined with Secukinumab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Secukinumab is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Secukinumab.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be increased when combined with Secukinumab.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be increased when combined with Secukinumab.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Secukinumab.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be increased when combined with Secukinumab.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be increased when combined with Secukinumab.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Alirocumab.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Secukinumab.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Evolocumab.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be increased when combined with Secukinumab.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Idarucizumab.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Secukinumab.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Secukinumab is combined with Asfotase alfa.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Secukinumab.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be increased when combined with Secukinumab.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Secukinumab.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be increased when combined with Secukinumab.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Daratumumab.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Secukinumab.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Secukinumab.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Necitumumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Elotuzumab is combined with Secukinumab.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Secukinumab.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Secukinumab is combined with Tetanus immune globulin, human.]
[B01AC27, selexipag, The metabolism of Selexipag can be increased when combined with Secukinumab.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be increased when combined with Secukinumab.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be increased when combined with Secukinumab.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be increased when combined with Secukinumab.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be increased when combined with Secukinumab.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Ixekizumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Reslizumab is combined with Secukinumab.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Secukinumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Secukinumab.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be increased when combined with Secukinumab.]
[R06AB01, brompheniramine, The metabolism of Brompheniramine can be increased when combined with Secukinumab.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Secukinumab.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Atezolizumab.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be increased when combined with Secukinumab.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be increased when combined with Secukinumab.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be increased when combined with Secukinumab.]
[N05BE01, buspirone, The metabolism of Buspirone can be increased when combined with Secukinumab.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Secukinumab.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Secukinumab.]
[P01BE02, artemether, The metabolism of Artemether can be increased when combined with Secukinumab.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be increased when combined with Secukinumab.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Olaratumab is combined with Secukinumab.]
[S01GX07, azelastine, The metabolism of Azelastine can be increased when combined with Secukinumab.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be increased when combined with Secukinumab.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Secukinumab.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be increased when combined with Secukinumab.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be increased when combined with Secukinumab.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Avelumab.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Ocrelizumab.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Dupilumab.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be increased when combined with Secukinumab.]
[N06BC01, caffeine, The metabolism of Caffeine can be increased when combined with Secukinumab.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Secukinumab.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Secukinumab.]
[J05AE09, tipranavir, The metabolism of Tipranavir can be increased when combined with Secukinumab.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be increased when combined with Secukinumab.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Secukinumab.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be increased when combined with Secukinumab.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Durvalumab.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Secukinumab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Sarilumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Guselkumab.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be increased when combined with Secukinumab.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Secukinumab.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Secukinumab.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Secukinumab.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Secukinumab.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Secukinumab.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Secukinumab.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Secukinumab.]
[J05AG03, efavirenz, The metabolism of Efavirenz can be increased when combined with Secukinumab.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be increased when combined with Secukinumab.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Secukinumab.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Secukinumab.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Secukinumab.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Secukinumab.]
[J05AX18, letermovir, The metabolism of Letermovir can be increased when combined with Secukinumab.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Benralizumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Emicizumab.]
[N01BX04, capsaicin, The metabolism of Capsaicin can be increased when combined with Secukinumab.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be increased when combined with Secukinumab.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Secukinumab.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Secukinumab.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be increased when combined with Secukinumab.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Burosumab.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be increased when combined with Secukinumab.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Erenumab.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Secukinumab is combined with Baricitinib.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be increased when combined with Secukinumab.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be increased when combined with Secukinumab.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be increased when combined with Secukinumab.]
[H01CC03, elagolix, The metabolism of Elagolix can be increased when combined with Secukinumab.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be increased when combined with Secukinumab.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Tildrakizumab.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be increased when combined with Secukinumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Mogamulizumab.]
[N03AX17, stiripentol, The metabolism of Stiripentol can be increased when combined with Secukinumab.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Lanadelumab.]
[J05AG06, doravirine, The metabolism of Doravirine can be increased when combined with Secukinumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Fremanezumab.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Secukinumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Galcanezumab.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Secukinumab.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be increased when combined with Secukinumab.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be increased when combined with Secukinumab.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be increased when combined with Secukinumab.]
[M03BA02, carisoprodol, The metabolism of Carisoprodol can be increased when combined with Secukinumab.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be increased when combined with Secukinumab.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be increased when combined with Secukinumab.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Carmustine can be increased when combined with Secukinumab.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Secukinumab.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be increased when combined with Secukinumab.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Secukinumab.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be increased when combined with Secukinumab.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be increased when combined with Secukinumab.]
[N06AX27, esketamine, The metabolism of Esketamine can be increased when combined with Secukinumab.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Secukinumab.]
[J01FA09, clarithromycin, The metabolism of Clarithromycin can be increased when combined with Secukinumab.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Secukinumab.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Romosozumab.]
[N05BA09, clobazam, The metabolism of Clobazam can be increased when combined with Secukinumab.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Secukinumab is combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Candesartan can be increased when combined with Secukinumab.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Secukinumab.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Secukinumab is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Secukinumab.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Secukinumab is combined with Polatuzumab vedotin.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Secukinumab.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be increased when combined with Secukinumab.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Secukinumab is combined with Upadacitinib.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be increased when combined with Secukinumab.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Secukinumab.]
[N07XX11, pitolisant, The metabolism of Pitolisant can be increased when combined with Secukinumab.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Secukinumab.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Secukinumab.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be increased when combined with Secukinumab.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Brolucizumab.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be increased when combined with Secukinumab.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Secukinumab.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Secukinumab is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Secukinumab.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Secukinumab is combined with Trastuzumab deruxtecan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Secukinumab is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Secukinumab.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Secukinumab.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be increased when combined with Secukinumab.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be increased when combined with Secukinumab.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be increased when combined with Secukinumab.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be increased when combined with Secukinumab.]
[N05CM21, lemborexant, The metabolism of Lemborexant can be increased when combined with Secukinumab.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Secukinumab.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Secukinumab.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Eptinezumab.]
[H02CA02, osilodrostat, The metabolism of Osilodrostat can be increased when combined with Secukinumab.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be increased when combined with Secukinumab.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be increased when combined with Secukinumab.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be increased when combined with Secukinumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Secukinumab is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be increased when combined with Secukinumab.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be increased when combined with Secukinumab.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be increased when combined with Secukinumab.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be increased when combined with Secukinumab.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be increased when combined with Secukinumab.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be increased when combined with Secukinumab.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Secukinumab.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Secukinumab.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Secukinumab.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Secukinumab is combined with Sacituzumab govitecan.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be increased when combined with Secukinumab.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Fluprednidene is combined with Secukinumab.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be increased when combined with Secukinumab.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be increased when combined with Secukinumab.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Secukinumab is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Secukinumab.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be increased when combined with Secukinumab.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Secukinumab.]
[P01BB01, proguanil, The metabolism of Proguanil can be increased when combined with Secukinumab.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Secukinumab is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be increased when combined with Secukinumab.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be increased when combined with Secukinumab.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Secukinumab.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be increased when combined with Secukinumab.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be increased when combined with Secukinumab.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be increased when combined with Secukinumab.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be increased when combined with Secukinumab.]
[M01AB08, etodolac, The metabolism of Etodolac can be increased when combined with Secukinumab.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be increased when combined with Secukinumab.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Secukinumab.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Ansuvimab.]
[L02BX04, relugolix, The metabolism of Relugolix can be increased when combined with Secukinumab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Margetuximab.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Secukinumab is combined with Voclosporin.]
[N03AX10, felbamate, The metabolism of Felbamate can be increased when combined with Secukinumab.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be increased when combined with Secukinumab.]
[G04CB01, finasteride, The metabolism of Finasteride can be increased when combined with Secukinumab.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Secukinumab.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Secukinumab.]
[R03CC15, formoterol, The metabolism of Formoterol can be increased when combined with Secukinumab.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be increased when combined with Secukinumab.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Secukinumab.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Secukinumab.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Secukinumab is combined with Loncastuximab tesirine.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be increased when combined with Secukinumab.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Amivantamab.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Secukinumab.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Sotrovimab.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Secukinumab.]
[N06AB04, citalopram, The metabolism of Citalopram can be increased when combined with Secukinumab.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Aducanumab.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Secukinumab is combined with Pegcetacoplan.]
[C03DA05, finerenone, The metabolism of Finerenone can be increased when combined with Secukinumab.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Secukinumab is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be increased when combined with Secukinumab.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Anifrolumab.]
[L01XX74, belzutifan, The metabolism of Belzutifan can be increased when combined with Secukinumab.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be increased when combined with Secukinumab.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Secukinumab is combined with Tisotumab vedotin.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be increased when combined with Secukinumab.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be increased when combined with Secukinumab.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be increased when combined with Secukinumab.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Secukinumab.]
[N06AX25, St. John's wort extract, The metabolism of St. John's Wort can be increased when combined with Secukinumab.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Secukinumab is combined with Ropeginterferon alfa-2b.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Tralokinumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Sutimlimab.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be increased when combined with Secukinumab.]
[N01BB10, levobupivacaine, The metabolism of Levobupivacaine can be increased when combined with Secukinumab.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Secukinumab.]
[S01EA04, clonidine, The metabolism of Clonidine can be increased when combined with Secukinumab.]
[C01EB24, mavacamten, The metabolism of Mavacamten can be increased when combined with Secukinumab.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be increased when combined with Secukinumab.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Secukinumab is combined with Deucravacitinib.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Tremelimumab.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be increased when combined with Secukinumab.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be increased when combined with Secukinumab.]
[N05AH02, clozapine, The metabolism of Clozapine can be increased when combined with Secukinumab.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Ublituximab.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Panitumumab is combined with Secukinumab.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Codeine can be increased when combined with Secukinumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Secukinumab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Secukinumab is combined with Leflunomide.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be increased when combined with Secukinumab.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Secukinumab.]
[J01FA15, telithromycin, The metabolism of Telithromycin can be increased when combined with Secukinumab.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be increased when combined with Secukinumab.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be increased when combined with Secukinumab.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be increased when combined with Secukinumab.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be increased when combined with Secukinumab.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be increased when combined with Secukinumab.]
[L01EA01, imatinib, The metabolism of Imatinib can be increased when combined with Secukinumab.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be increased when combined with Secukinumab.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be increased when combined with Secukinumab.]
[S01AE04, lomefloxacin, The metabolism of Lomefloxacin can be increased when combined with Secukinumab.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be increased when combined with Secukinumab.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Secukinumab is combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be increased when combined with Secukinumab.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be increased when combined with Secukinumab.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Secukinumab.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Secukinumab.]
[N06AX07, minaprine, The metabolism of Minaprine can be increased when combined with Secukinumab.]
[S01XA18, cyclosporine, Secukinumab may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Moclobemide can be increased when combined with Secukinumab.]
[N06BA07, modafinil, The metabolism of Modafinil can be increased when combined with Secukinumab.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Secukinumab.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be increased when combined with Secukinumab.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Secukinumab.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Secukinumab.]
[J05AF10, entecavir, The metabolism of Entecavir can be increased when combined with Secukinumab.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be increased when combined with Secukinumab.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be increased when combined with Secukinumab.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be increased when combined with Secukinumab.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Secukinumab.]
[J04BA02, dapsone, The metabolism of Dapsone can be increased when combined with Secukinumab.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Secukinumab.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be increased when combined with Secukinumab.]
[A04AD11, nabilone, The metabolism of Nabilone can be increased when combined with Secukinumab.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be increased when combined with Secukinumab.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be increased when combined with Secukinumab.]
[N06AX06, nefazodone, The metabolism of Nefazodone can be increased when combined with Secukinumab.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be increased when combined with Secukinumab.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Secukinumab.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be increased when combined with Secukinumab.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Secukinumab.]
[N06AB10, escitalopram, The metabolism of Escitalopram can be increased when combined with Secukinumab.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be increased when combined with Secukinumab.]
[N06AA01, desipramine, The metabolism of Desipramine can be increased when combined with Secukinumab.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Secukinumab.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Secukinumab.]
[S03BA01, dexamethasone, The metabolism of Dexamethasone can be increased when combined with Secukinumab.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be increased when combined with Secukinumab.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be increased when combined with Secukinumab.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Secukinumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be increased when combined with Secukinumab.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be increased when combined with Secukinumab.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be increased when combined with Secukinumab.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be increased when combined with Secukinumab.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be increased when combined with Secukinumab.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be increased when combined with Secukinumab.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be increased when combined with Secukinumab.]
[N05BA01, diazepam, The metabolism of Diazepam can be increased when combined with Secukinumab.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be increased when combined with Secukinumab.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Secukinumab.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be increased when combined with Secukinumab.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Secukinumab.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be increased when combined with Secukinumab.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Secukinumab is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Secukinumab.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Secukinumab is combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Secukinumab.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be increased when combined with Secukinumab.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Secukinumab.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Secukinumab.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Secukinumab.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Secukinumab.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be increased when combined with Secukinumab.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Secukinumab.]
[J05AE08, atazanavir, The metabolism of Atazanavir can be increased when combined with Secukinumab.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be increased when combined with Secukinumab.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be increased when combined with Secukinumab.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Secukinumab.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be increased when combined with Secukinumab.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be increased when combined with Secukinumab.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be increased when combined with Secukinumab.]
[N05CD10, quazepam, The metabolism of Quazepam can be increased when combined with Secukinumab.]
[A03FA02, cisapride, The metabolism of Cisapride can be increased when combined with Secukinumab.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Secukinumab.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be increased when combined with Secukinumab.]
[C01BA03, disopyramide, The metabolism of Disopyramide can be increased when combined with Secukinumab.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Secukinumab is combined with Human Rho(D) immune globulin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Disulfiram can be increased when combined with Secukinumab.]
[N07XX02, riluzole, The metabolism of Riluzole can be increased when combined with Secukinumab.]
[N05AX08, risperidone, The metabolism of Risperidone can be increased when combined with Secukinumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Secukinumab.]
[N01BB09, ropivacaine, The metabolism of Ropivacaine can be increased when combined with Secukinumab.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Secukinumab.]
[A04AD12, aprepitant, The metabolism of Aprepitant can be increased when combined with Secukinumab.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Secukinumab.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Secukinumab.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be increased when combined with Secukinumab.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be increased when combined with Secukinumab.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be increased when combined with Secukinumab.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Secukinumab.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be increased when combined with Secukinumab.]
[A03FA03, domperidone, The metabolism of Domperidone can be increased when combined with Secukinumab.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be increased when combined with Secukinumab.]
[N06AA12, doxepin, The metabolism of Doxepin can be increased when combined with Secukinumab.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Secukinumab.]
[N06AB06, sertraline, The metabolism of Sertraline can be increased when combined with Secukinumab.]
[N01AB08, sevoflurane, The metabolism of Sevoflurane can be increased when combined with Secukinumab.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be increased when combined with Secukinumab.]
[C07AB13, talinolol, The metabolism of Talinolol can be increased when combined with Secukinumab.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Secukinumab.]
[J01MA05, temafloxacin, The metabolism of Temafloxacin can be increased when combined with Secukinumab.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Secukinumab.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be increased when combined with Secukinumab.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be increased when combined with Secukinumab.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be increased when combined with Secukinumab.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Secukinumab.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Secukinumab.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be increased when combined with Secukinumab.]
[C03CA04, torsemide, The metabolism of Torasemide can be increased when combined with Secukinumab.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Secukinumab.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Secukinumab is combined with Trofosfamide.]
[N01AB04, enflurane, The metabolism of Enflurane can be increased when combined with Secukinumab.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Secukinumab is combined with Human varicella-zoster immune globulin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Secukinumab.]
[S01GX10, epinastine, The metabolism of Epinastine can be increased when combined with Secukinumab.]
[N06AX16, venlafaxine, The metabolism of Venlafaxine can be increased when combined with Secukinumab.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Secukinumab.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Secukinumab.]
[N03AX15, zonisamide, The metabolism of Zonisamide can be increased when combined with Secukinumab.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be increased when combined with Secukinumab.]
[N05AX11, zotepine, The metabolism of Zotepine can be increased when combined with Secukinumab.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Secukinumab.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be increased when combined with Secukinumab.]
[S01AA17, erythromycin, The metabolism of Erythromycin can be increased when combined with Secukinumab.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be increased when combined with Secukinumab.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be increased when combined with Secukinumab.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Secukinumab.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Secukinumab.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Secukinumab.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be increased when combined with Secukinumab.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Secukinumab.]
[R03BA09, fluticasone furoate, The metabolism of Fluticasone furoate can be increased when combined with Secukinumab.]
[R03BA05, fluticasone, The metabolism of Fluticasone can be increased when combined with Secukinumab.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be increased when combined with Secukinumab.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Secukinumab.]
[N03AD01, ethosuximide, The metabolism of Ethosuximide can be increased when combined with Secukinumab.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be increased when combined with Secukinumab.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be increased when combined with Secukinumab.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Secukinumab.]
[N05AE03, sertindole, The metabolism of Sertindole can be increased when combined with Secukinumab.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Secukinumab.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Secukinumab.]
[R06AX12, terfenadine, The metabolism of Terfenadine can be increased when combined with Secukinumab.]
[N06AX12, bupropion, The metabolism of Bupropion can be increased when combined with Secukinumab.]
[N06AB08, fluvoxamine, The metabolism of Fluvoxamine can be increased when combined with Secukinumab.]
[C01BB03, tocainide, The metabolism of Tocainide can be increased when combined with Secukinumab.]
[C01BC08, encainide, The metabolism of Encainide can be increased when combined with Secukinumab.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Secukinumab.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Secukinumab.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Secukinumab.]
[C08CA02, felodipine, The metabolism of Felodipine can be increased when combined with Secukinumab.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be increased when combined with Secukinumab.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be increased when combined with Secukinumab.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Secukinumab.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Secukinumab.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be increased when combined with Secukinumab.]
[C01BC04, flecainide, The metabolism of Flecainide can be increased when combined with Secukinumab.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Secukinumab.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Secukinumab.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be increased when combined with Secukinumab.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be increased when combined with Secukinumab.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Secukinumab.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Fluocortolone is combined with Secukinumab.]
[V03AZ01, ethanol, The metabolism of Ethanol can be increased when combined with Secukinumab.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Secukinumab.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Secukinumab.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be increased when combined with Secukinumab.]
[N06AB03, fluoxetine, The metabolism of Fluoxetine can be increased when combined with Secukinumab.]
[N05CD01, flurazepam, The metabolism of Flurazepam can be increased when combined with Secukinumab.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be increased when combined with Secukinumab.]
[L02BB01, flutamide, The metabolism of Flutamide can be increased when combined with Secukinumab.]
[L01BC03, tegafur, The metabolism of Tegafur can be increased when combined with Secukinumab.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be increased when combined with Secukinumab.]
[N06DA04, galantamine, The metabolism of Galantamine can be increased when combined with Secukinumab.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Secukinumab.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Secukinumab.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be increased when combined with Secukinumab.]
[J05AG04, etravirine, The metabolism of Etravirine can be increased when combined with Secukinumab.]
[N03AD03, methsuximide, The metabolism of Methsuximide can be increased when combined with Secukinumab.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be increased when combined with Secukinumab.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be increased when combined with Secukinumab.]
[A10BB01, glyburide, The metabolism of Glyburide can be increased when combined with Secukinumab.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be increased when combined with Secukinumab.]
[A10BB07, glipizide, The metabolism of Glipizide can be increased when combined with Secukinumab.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Secukinumab.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Secukinumab.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Secukinumab.]
[C07AB09, esmolol, The metabolism of Esmolol can be increased when combined with Secukinumab.]
[B01AA12, fluindione, The metabolism of Fluindione can be increased when combined with Secukinumab.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be increased when combined with Secukinumab.]
[N05AD01, haloperidol, The metabolism of Haloperidol can be increased when combined with Secukinumab.]
[N01AB01, halothane, The metabolism of Halothane can be increased when combined with Secukinumab.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be increased when combined with Secukinumab.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Secukinumab.]
[C09CA01, losartan, The metabolism of Losartan can be increased when combined with Secukinumab.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Secukinumab.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Secukinumab.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be increased when combined with Secukinumab.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be increased when combined with Secukinumab.]
[C08CA10, nilvadipine, The metabolism of Nilvadipine can be increased when combined with Secukinumab.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be increased when combined with Secukinumab.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be increased when combined with Secukinumab.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be increased when combined with Secukinumab.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Secukinumab.]
[N05BB01, hydroxyzine, The metabolism of Hydroxyzine can be increased when combined with Secukinumab.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be increased when combined with Secukinumab.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be increased when combined with Secukinumab.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Secukinumab.]
[N06AA02, imipramine, The metabolism of Imipramine can be increased when combined with Secukinumab.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Secukinumab.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Secukinumab is combined with Tixocortol.]
[M03BX02, tizanidine, The metabolism of Tizanidine can be increased when combined with Secukinumab.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Secukinumab.]
[S01BC01, indomethacin, The metabolism of Indomethacin can be increased when combined with Secukinumab.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Secukinumab.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Secukinumab.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Secukinumab.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be increased when combined with Secukinumab.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Ranibizumab is combined with Secukinumab.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be increased when combined with Secukinumab.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be increased when combined with Secukinumab.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be increased when combined with Secukinumab.]
[L01XX35, anagrelide, The metabolism of Anagrelide can be increased when combined with Secukinumab.]
[C07AA01, alprenolol, The metabolism of Alprenolol can be increased when combined with Secukinumab.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Secukinumab.]
[V03AB01, ipecac, The metabolism of Ipecac can be increased when combined with Secukinumab.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be increased when combined with Secukinumab.]
[N01AB06, isoflurane, The metabolism of Isoflurane can be increased when combined with Secukinumab.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Secukinumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be increased when combined with Secukinumab.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be increased when combined with Secukinumab.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be increased when combined with Secukinumab.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Abatacept is combined with Secukinumab.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be increased when combined with Secukinumab.]
[C07AG01, labetalol, The metabolism of Labetalol can be increased when combined with Secukinumab.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be increased when combined with Secukinumab.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Secukinumab.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Secukinumab.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be increased when combined with Secukinumab.]
[N02CA07, lisuride, The metabolism of Lisuride can be increased when combined with Secukinumab.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Secukinumab.]
[A07DA03, loperamide, The metabolism of Loperamide can be increased when combined with Secukinumab.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be increased when combined with Secukinumab.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Secukinumab.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Secukinumab.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Secukinumab.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be increased when combined with Secukinumab.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be increased when combined with Secukinumab.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Secukinumab.]
[R06AE05, meclizine, The metabolism of Meclizine can be increased when combined with Secukinumab.]
[N05CH01, melatonin, The metabolism of Melatonin can be increased when combined with Secukinumab.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Secukinumab.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Secukinumab.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be increased when combined with Secukinumab.]
[N03AA01, mephobarbital, The metabolism of Methylphenobarbital can be increased when combined with Secukinumab.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be increased when combined with Secukinumab.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be increased when combined with Secukinumab.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be increased when combined with Secukinumab.]
[N07BC02, methadone, The metabolism of Methadone can be increased when combined with Secukinumab.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be increased when combined with Secukinumab.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Secukinumab.]
[L01BA04, pemetrexed, The metabolism of Pemetrexed can be increased when combined with Secukinumab.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Secukinumab.]
[N05AA02, methotrimeprazine, The metabolism of Methotrimeprazine can be increased when combined with Secukinumab.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be increased when combined with Secukinumab.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be increased when combined with Secukinumab.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Secukinumab.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Secukinumab.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be increased when combined with Secukinumab.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Secukinumab.]
[A03FA01, metoclopramide, The metabolism of Metoclopramide can be increased when combined with Secukinumab.]
[C07AB02, metoprolol, The metabolism of Metoprolol can be increased when combined with Secukinumab.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be increased when combined with Secukinumab.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be increased when combined with Secukinumab.]
[N06AX03, mianserin, The metabolism of Mianserin can be increased when combined with Secukinumab.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be increased when combined with Secukinumab.]
[N05CD08, midazolam, The metabolism of Midazolam can be increased when combined with Secukinumab.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Secukinumab.]
[C09CA03, valsartan, The metabolism of Valsartan can be increased when combined with Secukinumab.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Secukinumab.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be increased when combined with Secukinumab.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Secukinumab.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be increased when combined with Secukinumab.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be increased when combined with Secukinumab.]
[N02AA01, morphine, The metabolism of Morphine can be increased when combined with Secukinumab.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be increased when combined with Secukinumab.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Secukinumab.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be increased when combined with Secukinumab.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Secukinumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Secukinumab.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Secukinumab.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be increased when combined with Secukinumab.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be increased when combined with Secukinumab.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be increased when combined with Secukinumab.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Secukinumab.]
[C07AA12, nadolol, The metabolism of Nadolol can be increased when combined with Secukinumab.]
[N04BC04, ropinirole, The metabolism of Ropinirole can be increased when combined with Secukinumab.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Secukinumab.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be increased when combined with Secukinumab.]
[M02AA12, naproxen, The metabolism of Naproxen can be increased when combined with Secukinumab.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be increased when combined with Secukinumab.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be increased when combined with Secukinumab.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Secukinumab.]
[L02BG04, letrozole, The metabolism of Letrozole can be increased when combined with Secukinumab.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be increased when combined with Secukinumab.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be increased when combined with Secukinumab.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Secukinumab.]
[C08CA04, nicardipine, The metabolism of Nicardipine can be increased when combined with Secukinumab.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be increased when combined with Secukinumab.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be increased when combined with Secukinumab.]
[N07BA01, nicotine, The metabolism of Nicotine can be increased when combined with Secukinumab.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be increased when combined with Secukinumab.]
[C08CA07, nisoldipine, The metabolism of Nisoldipine can be increased when combined with Secukinumab.]
[C08CA08, nitrendipine, The metabolism of Nitrendipine can be increased when combined with Secukinumab.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be increased when combined with Secukinumab.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Secukinumab.]
[C02KX01, bosentan, The metabolism of Bosentan can be increased when combined with Secukinumab.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Secukinumab.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Rilonacept is combined with Secukinumab.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be increased when combined with Secukinumab.]
[N02AA02, opium, The metabolism of Opium can be increased when combined with Secukinumab.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be increased when combined with Secukinumab.]
[C07AA02, oxprenolol, The metabolism of Oxprenolol can be increased when combined with Secukinumab.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be increased when combined with Secukinumab.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be increased when combined with Secukinumab.]
[N05AH05, asenapine, The metabolism of Asenapine can be increased when combined with Secukinumab.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Secukinumab.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be increased when combined with Secukinumab.]
[C07AA23, penbutolol, The metabolism of Penbutolol can be increased when combined with Secukinumab.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Secukinumab.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Secukinumab.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Secukinumab.]
[N05CA01, pentobarbital, The metabolism of Pentobarbital can be increased when combined with Secukinumab.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Secukinumab.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be increased when combined with Secukinumab.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be increased when combined with Secukinumab.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Edrecolomab.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be increased when combined with Secukinumab.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Secukinumab.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be increased when combined with Secukinumab.]
[A10BA01, phenformin, The metabolism of Phenformin can be increased when combined with Secukinumab.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be increased when combined with Secukinumab.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Secukinumab.]
[M02AA01, phenylbutazone, The metabolism of Phenylbutazone can be increased when combined with Secukinumab.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be increased when combined with Secukinumab.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be increased when combined with Secukinumab.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Secukinumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Secukinumab.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Secukinumab.]
[C07AA03, pindolol, The metabolism of Pindolol can be increased when combined with Secukinumab.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be increased when combined with Secukinumab.]
[J05AE01, saquinavir, The metabolism of Saquinavir can be increased when combined with Secukinumab.]
[P02CB01, piperazine, The metabolism of Piperazine can be increased when combined with Secukinumab.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be increased when combined with Secukinumab.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be increased when combined with Secukinumab.]
[J01MA11, grepafloxacin, The metabolism of Grepafloxacin can be increased when combined with Secukinumab.]
[J05AG02, delavirdine, The metabolism of Delavirdine can be increased when combined with Secukinumab.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be increased when combined with Secukinumab.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Secukinumab.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be increased when combined with Secukinumab.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be increased when combined with Secukinumab.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Ustekinumab is combined with Secukinumab.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be increased when combined with Secukinumab.]
[A03AE01, alosetron, The metabolism of Alosetron can be increased when combined with Secukinumab.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Secukinumab.]
[J05AE03, ritonavir, The metabolism of Ritonavir can be increased when combined with Secukinumab.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be increased when combined with Secukinumab.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be increased when combined with Secukinumab.]
[C07AB01, practolol, The metabolism of Practolol can be increased when combined with Secukinumab.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be increased when combined with Secukinumab.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Secukinumab.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Secukinumab.]
[P01BA03, primaquine, The metabolism of Primaquine can be increased when combined with Secukinumab.]
[N03AA03, primidone, The metabolism of Primidone can be increased when combined with Secukinumab.]
[C01BA02, procainamide, The metabolism of Procainamide can be increased when combined with Secukinumab.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Secukinumab.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Secukinumab.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be increased when combined with Secukinumab.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Secukinumab.]
[N05AA03, promazine, The metabolism of Promazine can be increased when combined with Secukinumab.]
[R06AD02, promethazine, The metabolism of Promethazine can be increased when combined with Secukinumab.]
[C01BC03, propafenone, The metabolism of Propafenone can be increased when combined with Secukinumab.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Secukinumab.]
[N01AX10, propofol, The metabolism of Propofol can be increased when combined with Secukinumab.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be increased when combined with Secukinumab.]
[C07AA05, propranolol, The metabolism of Propranolol can be increased when combined with Secukinumab.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Secukinumab.]
[R03DC03, montelukast, The metabolism of Montelukast can be increased when combined with Secukinumab.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Secukinumab.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Secukinumab.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be increased when combined with Secukinumab.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Secukinumab.]
[P01BC01, quinine, The metabolism of Quinine can be increased when combined with Secukinumab.]
[A02BA02, ranitidine, The metabolism of Ranitidine can be increased when combined with Secukinumab.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Secukinumab.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be increased when combined with Secukinumab.]
[N04BD01, selegiline, The metabolism of Selegiline can be increased when combined with Secukinumab.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Secukinumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Secukinumab.]
[C07AA07, sotalol, The metabolism of Sotalol can be increased when combined with Secukinumab.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Secukinumab.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Secukinumab.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Secukinumab.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be increased when combined with Secukinumab.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be increased when combined with Secukinumab.]
